New dopamine receptor, D2(Longer), with unique TG splice site, in human brain

Molecular Brain Research

Volumn 76, Issue 1, 2000, Pages 132-141

  Seeman, Philip ^a,b   Nam, Diane ^a   Ulpian, Carla ^a   Liu, Ivy S C ^a,b   Tallerico, Teresa ^a,b  

^a Med Sci Bldg 8 Taddle Creek R ^*  (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

D2 mRNA; D2 splice variant; D2(Longer); Dopamine receptor; Psychosis

Indexed keywords

CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; LOXAPINE; MESSENGER RNA; NORADRENALIN; OLANZAPINE; QUETIAPINE; RACLOPRIDE; REMOXIPRIDE; RISPERIDONE; SEROTONIN; SERTINDOLE; SPIPERONE; THIORIDAZINE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; AUTOPSY; CORPUS STRIATUM; FEMALE; HUMAN; HUMAN TISSUE; MALE; MUTATION; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; BASE SEQUENCE; BRAIN; CAUDATE NUCLEUS; DNA, COMPLEMENTARY; FEMALE; FRONTAL LOBE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PSYCHOTIC DISORDERS; PUTAMEN; RECEPTORS, DOPAMINE D2; RNA; RNA SPLICING; SCHIZOPHRENIA;

EID: 0034629227     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(99)00343-5     Document Type: Article

References (50)

1. Bai G., Lipton S.A. Aberrant RNA splicing in sporadic amyotrophic lateral sclerosis. Neuron. 20:1998;363-366.
2. Burns C.M., Chu H., Rueter S.M., Hutchinson L.K., Canton H., Sanders-Bush E., Emeson R.B. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature. 387:1997;303-308.
3. Castro S.W., Strange P.G. Differences in the ligand binding properties of the short and long versions of the D2 dopamine receptor. J. Neurochem. 60:1993;372-375.
4. Cichon S., Nöthen M., Stöber G., Schroers R., Albus M., Maier W., Rietschel M., Körner J., Weigelt B., Franzek E., Wildenauer D., Fimmers R., Propping P. Systematic screening for mutations in the 5′-regulatory region of the human dopamine D1 receptor (DRD1) gene in patients with schizophrenia and bipolar affective disorder. Am. J. Med. Gen. 67:1996;424-428.
5. Coon H., Byerley W., Holik J., Hoff M., Myles-Worsley M., Lannfelt L., Sokoloff P., Schwartz J.-C., Waldo M., Freedman R., Plaetke R. Linkage analysis of schizophrenia with five dopamine receptor genes in nine pedigrees. Am. J. Hum. Genet. 52:1993;327-334.
6. 2 dopamine receptor missense variants. J. Biol. Chem. 271:1996;26013-26017.
7. 2 receptor: two molecular forms generated by alternative splicing. EMBO J. 8:1989;4025-4034.
8. Damask S.P., Bovenkerk K.A., de la Pena G., Hoversten K.M., Peters D.B., Valentine A.M., Meador-Woodruff J.H. Differential effects of clozapine and haloperidol on dopamine mRNA expression in rat striatum and cortex. Mol. Brain Res. 41:1996;241-249.
9. A receptor gene. J. Neurochem. 56:1991;1024-1029.
10. 2 receptor gene in alcoholism or schizophrenia. J. Am. Med. Assoc. 271:1994;204-208.
11. 1 receptors. Mol. Brain Res. 18:1993;290-296.
12. 2 dopamine receptor isoforms. Nature. 342:1989;923-926.
13. 2 dopamine receptor. Proc. Natl. Acad. Sci. U. S. A. 86:1989;9762-9766.
14. Hodges P., Scott J. Apolipoprotein B mRNA editing: a new tier for the control of gene expression. Trends Bol. Sci. 17:1992;77-81.
15. Hurley M.J., Stubbs C.M., Jenner P., Marsden C.D. Effect of chronic treatment with typical and atypical neuroleptics on the expression of dopamine D2 and D3 receptors in rat brain. Psychopharmacology. 128:1996;362-370.
16. Itokawa M., Arinami T., Futamura N., Hamaguchi H., Toru M. A structural polymorphism of human dopamine D2 receptor, D2(Ser311-Cys). Biochem. Biophys. Res. Commun. 196:1993;1369-1375.
17. Johnson S.A., Morgan D.G., Finch C.E. Extensive post-mortem stability of RNA from rat and human brain. J. Neurosci. Res. 16:1986;267-280.
18. Khan Z.U., Mrzljak L., Gutierrez A., de la Calle A., Goldman-Rakic P.S. Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc. Natl. Acad. Sci. U. S. A. 95:1998;7731-7736.
19. Levinson D.F., Mahtani M.M., Nancarrow D.J., Brown D.M., Kruglyak L., Kirby A., Hayward N.K., Crowe R.R., Andreasen N.C., Black D.W., Silverman J.M., Endicott J., Sharpe L., Mohs R.C., Siever L.J., Walters M.K., Lennon D.P., Jones H.L., Nertney D.A., Daly M.J., Gladis M., Mowry B.J. Genome scan of schizophrenia. Am. J. Psychiatry. 155:1998;741-750.
20. 125I ]2′-iodospiperone Psychopharmacology. 110:1993;27-36.
21. Glycine, is insensitive to dopamine and clozapine. Report of a homozygous individual. Am. J. Med. Gen. 61:1996;277-282.
22. 3 receptors. Mol. Pharmacol. 43:1993;749-754.
23. Meador-Woodruff J.H., Haroutunian V., Powchik P., Davidson M., Davis K.L., Watson S.J. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Arch. Gen. Psychiatry. 54:1997;1089-1095.
24. 2 dopamine receptor gene region and schizophrenia. Arch. Gen. Psychiatry. 48:1991;643-647.
25. Nakai K., Sakamoto H. Construction of a novel database containing aberrant splicing mutations of mammalian genes. Gene. 141:1994;171-177.
26. Neve K.A., Neve R.L., Fidel S., Janowsky A., Higgins G.A. Increased abundance of alternatively spliced forms of D2 dopamine receptor mRNA after denervation. Proc. Natl. Acad. Sci. U. S. A. 88:1991;2802-2806.
27. 3 receptor dimers and tetramers in brain and transfected cells. J. Biol. Chem. 272:1997;29229-29237.
28. Nöthen M.M., Wildenauer D., Cichon S., Albus M., Maier W., Minges J., Lichtermann D., Bondy B., Rietschel M., Kömer J., Fimmers R., Propping P. Dopamine D2 receptor molecular variant and schizophrenia. Lancet. 343:1994;1301-1302.
29. Ohara K., Ulpian C., Seeman P., Sunahara R., Niznik H.B. Schizophrenia: dopamine D1 receptor sequence is normal, but has DNA polymorphisms. Neuropsychopharmacology. 8:1993;131-135.
30. Perrett C.W., Whatley S.A., Ferrier I.N., Marchbanks R.M. Changes in relative levels of specific brain mRNA species associated with schizophrenia and depression. Mol. Brain Res. 12:1992;163-171.
31. 2 receptor isoforms in brain tissue from controls and schizophrenics. Mol. Brain Res. 25:1994;173-175.
32. Ross B.M., Knowler J.T., McCulloch J.T. On the stability of messenger RNA and ribosomal RNA in the brains of control human subjects and patients with Alzheimer's disease. J. Neurochem. 58:1992;1810-1819.
33. 2 receptor (DRD2) in schizophrenics reveals three polymorphisms but no structural change in the receptor. Genomics. 11:1991;8-14.
34. Sasaki T., Macciardi F.M., Badri F., Verga M., Meltzer H.Y., Lieberman J., Howard A., Bean G., Joffe R.T., Hudson C.J., Kennedy J.L. No evidence for association of dopamine D2 receptor variant (Ser311/Cys311) with major psychosis. Am. J. Med. Gen. 67:1996;415-417.
35. Scheer A., Cotecchia S. Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation. J. Recept. Signal Transduction Res. 17:1997;57-73.
36. 4 receptors by 2-fold in rats. Eur. J. Pharmacol., Mol Pharmacol. Sect. 289:1995;67-72.
37. Seeburg P.H., Higuchi M., Sprengel R. RNA editing of brain glutamate receptor channels: mechanism and physiology. Brain Res. Rev. 26:1998;217-229.
38. Seeman P. Brain dopamine receptors. Pharmacol. Rev. 32:1980;229-313.
39. Seeman P., Tallerico T. Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol. Psychiatry. 3:1998;123-134.
40. Seeman P., Van Tol H.H.M. Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15:1994;264-270.
41. Seeman P., Chau-Wong M., Tedesco J., Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc. Natl. Acad. Sci. U. S. A. 72:1975;4376-4380.
42. Seeman P., Niznik H.B., Guan H.-C., Booth G., Ulpian C. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc. Natl. Acad. Sci. U. S. A. 86:1989;10156-10160.
43. 2. Neuropsychopharmacology. 8:1993;137-142.
44. GLYCINE194, in Africans, but not in Caucasians. No association with schizophrenia. Am. J. Med. Gen. (Neuropsychiatric Genet.). 54:1994;384-390.
45. 2 receptor mRNA splice variants in the rat by solution hybridization/protection assay. Neurosci. Lett. 122:1991;37-40.
46. Tarn W.Y., Steitz J.A. Pre-mRNA splicing: the discovery of a new spliceosome doubles the challenge. Trends Biochem. Sci. 22:1997;132-137.
47. van Leeuwen F.W., de Kleijn D.P.V., van den Hurk H.H., Neubauer A., Sonnemans M.A.F., Sluijs J.A., Köycü S., Ramdjielal R.D.J., Salehi A., Martens G.J.M., Grosveld F.G., Burbach J.P.H., Hol E.M. Frameshifts mutants of β amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science. 279:1998;242-247.
48. van Leeuwen F.W., Burbach P.H., Hol E.M. Mutations in RNA: a first example of molecular misreading in Alzheimer's disease. Trends Neurosci. 21:1998;331-335.
49. 2 dopamine receptor mRNA level. Neurosci. Lett. 111:1990;303-308.
50. Zawarynski P., Tallerico T., Seeman P., Lee S.P., O'Dowd B.F., George S.R. Dopamine D2 receptor dimers in human and rat brain. FEBS Lett. 441:1998;383-386.